FTC Fights Nixing Of AndroGel Reverse Payment Suit
Law360 (June 10, 2010, 7:06 PM EDT) -- The Federal Trade Commission is challenging the dismissal of its claims accusing Solvay Pharmaceuticals Inc. of paying generic-drug makers not to compete with its testosterone supplement AndroGel, continuing the fight over so-called reverse payment settlements in the pharmaceutical industry.
In a filing Thursday in the U.S. District Court for the Northern District of Georgia, the FTC said it would appeal the court's April judgment throwing out its allegations with prejudice to the U.S. Court of Appeals for the Eleventh Circuit.
A spokesperson for the agency declined to comment.
Reverse payment settlements, in which brand-name drug companies pay generic-drug companies not to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!